Moloney murine leukemia virus (Mo-MuLV) induces T-cell lymphoma when inoculated into neonatal mice. This is a multistep process. Early events observed in infected mice include generalized hematopoietic hyperplasia in the spleen and appearance of mink cell focus-inducing (MCF) recombinants; end-stage tumors are characterized by insertional proviral activation of protooncogenes. We previously showed that an Mo-MuLV enhancer variant, Mo+PyF101
Moloney murine leukemia virus (Mo-MuLV) induces T-cell lymphoma in mice with a typical latency of 3-4 months. We previously described a preleukemic state in Mo-MuLVinoculated mice characterized by generalized hemotopoietic hyperplasia, predominantly in the spleen (1) . We also reported that a variant of Mo-MuLV, Mo+PyF101 Mo-MuLV, which contains polyoma F101 enhancer sequences inserted into the U3 region of the Mo-MuLV long terminal repeat (LTR), was defective both for induction of preleukemic hyperplasia and for leukemogenesis (1, 2) . Thus, Mo+-PyF101 Mo-MuLV is a useful tool for investigating preleukemic events in Mo-MuLV-induced leukemogenesis, since it is apparently unable to perform some function necessary for disease induction. In view of the fact that Mo+PyF101 Mo-MuLV is an enhancer variant of Mo-MuLV, it seems possible that it is defective in its ability to infect some cell type in the animal required by wild-type Mo-MuLV for efficient induction of leukemia.
A previously reported feature of MuLV-induced disease is the appearance of env gene recombinant (mink cell focusinducing or MCF) viruses at preleukemic times and in endstage tumors (3) (4) (5) . MCF viruses infect cells via a different receptor from that used by Mo-MuLV and are generated by recombination in vivo between the inoculated ecotropic MuLV and endogenous MuLV proviruses (3) . The high concentration of MCF viruses in end-stage tumors has led to the suggestion that they are important late in leukemogenesis (6) . Recent results from our laboratory have suggested a role for MCF recombinants early in leukemogenesis as well-i.e., in induction of preleukemic hyperplasia (7) .
In the experiments reported here, the basis for the leukemogenic defect of Mo+PyF101 Mo-MuLV was investigated further. We report here that Mo+PyF1O1-inoculated animals do not contain detectable MCF recombinants and that an artificially constructed Mo+PyF101 MCF does not propagate when inoculated into newborn mice. strains of mice, a low incidence of T-cell lymphomas was observed in Mo+PyF1O1 Mo-MuLV-inoculated animals after an extended latent period (Fig. lb) . Whereas 50% of wild-type Mo-MuLV-inoculated mice were moribund with leukemia at 14 weeks and 100% had died by 20 weeks, only 7% of Mo+PyF101 Mo-MuLV-inoculated mice developed leukemia at 14 weeks, and at 50 weeks only 62% had died. We are unable to account for the somewhat higher leukemogenicity of Mo+PyF101 Mo-MuLV in these later experiments in comparison with the original study, except that more animals were tested. Nevertheless, Mo+PyF1O1 Mo-MuLV should be viewed as having markedly decreased leukemogenicity compared with wild-type Mo-MuLV. Agar colony assays for hematopoiesis confirmed that the great majority of Mo+PyF1O1 Mo-MuLV-inoculated mice in the present study did not show splenic hyperplasia, consistent with our previous observations (1) .
MATERIALS AND METHODS
Absence of Detectable MCF Proviruses in Mo+PyF101 Mo-MuLV-Inoculated Mice. Since Mo+PyF1l1 Mo-MuLVinoculated mice are defective for induction of preleukemic splenic hyperplasia (1), and since MCF recombinants have been implicated in induction of hyperplasia (7), we examined preleukemic mice inoculated with wild-type or Mo+PyF101 Mo-MuLV for the presence of MCF proviruses. Fig. 2 shows Southern blot analysis of DNAs taken at preleukemic times (4-10 weeks) from wild-type and Mo+PyF1l1 Mo-MuLVinoculated mice. MCF recombinants from either wild-type or Mo+PyF1O1 Mo-MuLV would yield a unique 2.3-kilobase (kb) fragment after digestion with Xba I/BamHI and hybridization with an MCF recombinant-specific probe (Fig. 2a) . This MCF recombinant-specific band could be detected in 77% of wild-type Mo-MuLV-inoculated mice at preleukemic times ( Fig. 2b and Table 1 ). In contrast, no MCF provirus was detected in 20 Mo+PyF101 Mo-MuLV-inoculated mice examined at these times. Since Mo+PyF101 and wild-type Mo-MuLV-infected mice develop similar levels of viral infection at preleukemic times (2, 12) , the results suggested that Mo+PyF101 Mo-MuLV may be defective in generation or propagation of MCF recombinants.
Thymocytes from Mo+PyF101 Mo-MuLV-inoculated animals at 4-9 weeks were also cocultivated with NIH 3T3 fibroblasts, followed by serial passage to allow spread of low levels of virus. DNA from the cocultured and passaged NIH 3T3 cells also failed to reveal the presence of MCF recombinants by Southern blot analysis (not shown). Thus, by this more sensitive criterion, Mo+PyF101 Mo-MuLV did not generate MCF recombinants at preleukemic times.
Whereas MCF recombinants are often present at relatively low levels in preleukemic mice, end-stage Mo-MuLVinduced tumors generally have high levels of MCF proviruses (5, 13). As shown in Table 1 and Fig. 2c , five of five tumor DNAs from wild-type Mo-MuLV-inoculated mice showed the 2.3-kb MCF-specific proviral fragment at high concentrations. We also examined tumors arising at lower frequency and longer latency in Mo+PyF1O1 Mo-MuLV-inoculated mice ( Fig. 2c and (Fig. 3a) . (Fig. 3b) , although they did show the presence of Mo+PyF101 Mo-MuLV (not shown). Lack of Mo+PyF101 MCF provirus in the mice was not due to a defect in the cloned virus, since it could be detected in NIH 3T3 cells infected with the same pseudotypic mixture (not shown). These results confirmed that MCF recombinants are not detected in Mo+PyF101 Mo-MuLV-inoculated mice because they do not propagate efficiently in the animal.
DISCUSSION
We report here that inoculation of Mo+PyF101 Mo-MuLV into neonatal mice does not result in appearance ofdetectable MCF recombinants, either at preleukemic times or even in tumors that eventually develop. Presumably the addition of PyF101 enhancers to the Mo-MuLV LTR renders the virus incapable ofproductively infecting some cell type(s) that is an obligatory host of MCFs in vivo. These results suggest a basis for the leukemogenic defect of the Mo+PyF101 variant of Mo-MuLV.
We previously showed that Mo+PyF101 Mo-MuLV is defective in inducing preleukemic splenic hyperplasia (1) . On the other hand, Mo+PyF101 Mo-MuLV is capable of establishing high-level infection in thymocytes, which suggests that it should be able to carry out later events in leukemogenesis such as insertional activation of protooncogenes (5, (18) (19) (20) . The correlation between the inability of Mo+PyF101 Mo-MuLV to induce preleukemic hyperplasia and its failure to generate detectable MCF recombinants suggests a possible role for MCF recombinants early in the disease process. We recently proposed that preleukemic hyperplasia in the spleen may result from inhibitory effects on bone marrow hematopoiesis because of combined infection of bone marrow stroma with Mo-MuLV and MCF recombinant (7) . The defect of Mo+PyF101 Mo-MuLV in generation of preleukemic hyperplasia and of MCF recombinants is completely consistent with this notion.
The importance of MCF viruses in efficient leukemogenesis was also supported by comparison of different MoMuLV enhancer variants (Table 1) . Those variants that efficiently generated MCF recombinants were the most pathogenic, while those that could not were the least. With regard to the polyoma-containing variants, we previously showed that the exact organization of the PyF101 enhancers are important for the low leukemogenicity in that chimeric Mo-MuLV LTRs with related F441 and wild-type polyoma enhancers were not as tightly restricted for disease (14) . These viruses showed intermediate levels of MCF recombinant generation, consistent with their pathogenicity.
The results (Fig. 3) 
